Evogene Ltd.

NasdaqCM:EVGN Stock Report

Market Cap: US$7.8m

Evogene Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ofer Haviv

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure21.8yrs
CEO ownershipn/a
Management average tenure2.6yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 12

Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots

Evogene (NASDAQ:EVGN) said its unit Lavie Bio filed a registration package to the U.S. Environmental Protection Agency (EPA) for LAV.311, a bio-fungicide targeting fruit rots and powdery mildews. LAV.311 is based on a bacteria which is naturally present and has shown control of fruit rots and powdery mildew in grapes, strawberries, cucurbits, and fruiting vegetables, in over 30 trials conducted in the U.S., Europe and Israel, the company said in an Oct. 12 press release. "We are pleased to have reached this key product milestone and we are targeting the 2024 growing season for the commercial launch of this product," said Lavie CEO Guri Oron. EVGN -2.87% to $0.68 premarket Oct. 12
Seeking Alpha • Sep 21

Evogene unit launches 2nd-gen medical cannabis products in Israel

Evogene's (NASDAQ:EVGN) unit Canonic launched its second-generation medical cannabis products in Israel. The first product from this line is expected to debut for patients in early October and the rest will follow in the last quarter of the year to Q1 2023. The second-generation products are characterized by high THC and unique terpene profiles, the company said in a Sept. 21 press release. EVGN +1.33% to $0.94 premarket Sept. 21
Seeking Alpha • Sep 14

Lavie Bio appoints Guri Oron as CEO

Lavie Bio, a subsidiary of Evogene (NASDAQ:EVGN) notifies the appointment of Guri Oron as CEO of Lavie Bio, effective as of September 18, 2022. Most recently, Mr. Oron served at Viridix Ltd., an ag-tech company focused on precision irrigation.
Seeking Alpha • Aug 31

Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M

Evogene press release (NASDAQ:EVGN): Q2 GAAP EPS of -$0.42 misses by $0.23. Revenue of $0.55M (+292.9% Y/Y) beats by $0.33M.
Seeking Alpha • Aug 25

Evogene regains compliance with Nasdaq's minimum bid price requirement

Evogene (NASDAQ:EVGN) said it has regained compliance with Nasdaq's listing rule, which requires the computational biology company's ordinary shares to maintain a minimum bid price of $1.00 per share. The stock exchange has determined compliance after the closing bid price per share was at $1.00 or greater for prior 10 consecutive business days. Nasdaq now considers the matter closed. Shares were trading +2.63% pre-market. Source: Press Release
Seeking Alpha • Aug 17

Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement

Shares of Evogene (NASDAQ:EVGN), a developer of life-science based products, rose as much as 10.2% to $1.3 in Wednesday late afternoon trading after its unit Lavie Bio entered into a collaboration agreement with specialty minerals company ICL (NYSE:ICL). Under the deal, ICL will invest $10M in Lavie Bio, which develops microbiome-based products for use in the food and agriculture industry. The Israeli companies announced the deal after hours on Tuesday. The collaboration would focus on developing bio-stimulant products to enrich the efficiency of fertilizers, they said. Evogene (EVGN) shares had pared some gains and were trading 6.8% higher as of 1522 ET, while ICL stock was -0.9% at $10.04.
Seeking Alpha • Mar 22

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Evogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus. Biomica's lead product BMC128, 4 strain live microbiome consortia in immuno-oncology, is proceeding to clinical trials in Israel in Q2 2022, in combination with Bristol Myers' PD-1 Opdivo. Lavie Bio recently commercially launched result™, a microbiome-based ag-stimulant to increase yield and profitability in spring wheat. Modest initial 2022 sales are expected to increase in 2023 and beyond. AgPlenus is an ag-chemical company. Its lead product APH1 is a novel mode of action herbicide in the near "optimized lead" stage. A deal for APH1could be announced this year. The author believes that Evogene is currently undervalued. With numerous upcoming catalysts in 2022/2023, patient risk-tolerant investors could be handsomely rewarded in the next few years.
Seeking Alpha • Mar 03

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Evogene is a computational biology company that acts a technology hub, creating life science divisions and subsidiaries. Canonic is a subsidiary focused on discovering and developing non-GMO medical cannabis products. In October 2021, Canonic commercially launched G150 and G200, its first two MetaYield medical cannabis products in Israel which appears to be a success. Canonic has Israel's largest Cannabis R&D facility, is fully licensed, owns a state of the art 22,000 square foot greenhouse and molecular labs. It is progressing preclinically (and soon clinically) with its Precise medical cannabis program focused on the treatment of pain and inflammation. Canonic has recently begun shipping its proprietary seedling plants to Portugal in anticipation of a European launch in 2023. A U.S. launch is expected in 2024.
Seeking Alpha • Sep 14

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Canonic introduces their new proprietary cannabis strains and begins limited distribution in Israel. The company will make a full commercial release of the new products in 2022. Evogene’s other subsidiary, Lavie Bio, plans a commercial release of their bio-stimulate in 2022. The company’s Q2-2021 quarterly report shows net loss and low revenues, but plenty of operating cash. I give the company a neutral rating and recommend investors watch their developments and await revenue catalysts.

CEO Compensation Analysis

How has Ofer Haviv's remuneration changed compared to Evogene's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$18m

Mar 31 2026n/an/a

-US$19m

Dec 31 2025n/an/a

-US$14m

Sep 30 2025n/an/a

-US$11m

Jun 30 2025n/an/a

-US$13m

Mar 31 2025n/an/a

-US$15m

Dec 31 2024US$424kUS$374k

-US$13m

Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$19m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$401kUS$390k

-US$20m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$25m

Dec 31 2022US$464kUS$415k

-US$27m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$530kUS$420k

-US$28m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$592kUS$367k

-US$23m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$538kUS$366k

-US$18m

Compensation vs Market: Insufficient data to establish whether Ofer's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Ofer's compensation has increased whilst the company is unprofitable.

CEO

Ofer Haviv (60 yo)

21.8yrs
Tenure
US$424,000
Compensation

Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...

Leadership Team

NamePositionTenureCompensationOwnership
Ofer Haviv
CEO, President21.8yrsUS$424.00kno data
Yoash Zohar
Chief Executive Officer of Casterra Ag Ltd.2.7yrsUS$583.00kno data
Dan Gelvan
Chief Executive Officer of Ag Plenus Ltd.2.6yrsUS$369.00kno data
Ilia Zhidkov
Chief Technology Officerless than a yearno data0%
$ 0
Liat Wejgman
Vice President of Human Resources4.7yrsno datano data
Gabi Tarcic
Chief Development Officerless than a yearno data0.0071%
$ 559.4
2.6yrs
Average Tenure
59yo
Average Age

Experienced Management: EVGN's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ofer Haviv
CEO, President1.5yrsUS$424.00kno data
Dan Falk
Independent Director4.8yrsno data0%
$ 0
Nir Nimrodi
Independent Chairman4yrsno data0%
$ 0
Leon Recanati
Independent Director21.3yrsno data8.5%
$ 666.3k
Yael Margolin
Directorno datano datano data
Yoshinori Oikawa
Directorno datano datano data
Sarit Weiss-Firon
Independent Director10.1yrsno data0%
$ 0
John Irwin
Member of Scientific Advisory Boardless than a yearno datano data
Adrian Percy
Independent Director7.6yrsno data0%
$ 0
Dan Major
Member of Scientific Advisory Boardless than a yearno datano data
2.8yrs
Average Tenure
61yo
Average Age

Experienced Board: EVGN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 02:30
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evogene Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
David BegleiterDeutsche Bank
Hoonshik YangOppenheimer & Co. Inc.